ReviewMedicina (Kaunas, Lithuania)2023
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Toxicity reduction and immune reconstitution with adjuvant traditional Chinese medicine for postoperative ovarian cancer: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Immune checkpoint inhibitor-based combination therapy for platinum-resistant or platinum-refractory recurrent ovarian cancer: a systematic review and meta-analysis of prospective trials.Frontiers in oncology · 2026Pooled it
- Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.Cell reports. Medicine · 2025Trial
- Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.Journal of gynecologic oncology · 2025Trial
- Circular RNAs in ferroptosis regulation and tumor progression of gynecological and breast cancers: molecular mechanisms and therapeutic potential.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- ZNF217 promotes receptor tyrosine kinase plasticity and AXL-ERK dependency in ovarian cancer.bioRxiv : the preprint server for biology · 2026Article
- Bioactivity-guided evaluation of F7 fraction derived from Acalypha cuspidata on ovarian cancer models in vitro and in vivo.Journal, genetic engineering & biotechnology · 2026Article
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer.Research square · 2026Article
- Thiostrepton potentiates chemotherapy-induced cell death in cisplatin-resistant SKOV3 cells.BMC cancer · 2026Article
- Deep learning-based prediction of gene expression from histopathology identifies NR5A1 as a candidate biomarker and druggable target in high-grade serous ovarian carcinoma.Journal of ovarian research · 2026Article
- An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review.International journal of reproductive biomedicine · 2026Review
- Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues.Cancer reports (Hoboken, N.J.) · 2026Article
- Punicalagin Inhibits the Growth and Proliferation of Ovarian Epithelial Adenocarcinoma Cells Via Apoptosis and Autophagic Cell Death.Journal of biochemical and molecular toxicology · 2026Article
- Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure.Journal of ovarian research · 2026Review
- Extracellular vesicles derived from ovarian cancer cells promote tumor progression through m2 macrophage polarization and enhanced angiogenesis.BMC cancer · 2026Article
- Bioinformatics and clinical analysis of CETN2's impact on platinum resistance and prognosis in epithelial ovarian cancer.Journal of ovarian research · 2026Article
- Cell-intrinsic and tumor microenvironmental determinants of platinum resistance in epithelial ovarian cancer.Discover oncology · 2026Review
- Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.Clinical epigenetics · 2026Review
- CBX2 promotes cisplatin resistance in ovarian cancer via SIAH2-mediated β-catenin stabilization and ATG9B-dependent autophagy activation.Journal of ovarian research · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based chemotherapy is the backbone of treatment for ovarian cancer, and although the majority of patients initially have a platinum-sensitive disease, through multiple recurrences, they will acquire resistance. Platinum-resistant recurrent ovarian cancer has a poor prognosis and few treatment options with limited efficacy. Resistance to platinum compounds is a complex process involving multiple mechanisms pertaining not only to the tumoral cell but also to the tumoral microenvironment. In this review, we discuss the molecular mechanism involved in ovarian cancer cells' resistance to platinum-based chemotherapy, focusing on the alteration of drug influx and efflux pathways, DNA repair, the dysregulation of epigenetic modulation, and the involvement of the tumoral microenvironment in the acquisition of the platinum-resistant phenotype. Furthermore, we review promising alternative treatment approaches that may improve these patients' poor prognosis, discussing current strategies, novel combinations, and therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.